Special Interview with Dr. Dario Bottigliero
14 April 2025
We are interviewing Dr. Dario Bottigliero, Head of the Cardiology and Intensive Cardiac Care Unit at Victor Jousselin Hospital in Dreux, France, about a recent article titled "Safer Heart Stents: Drug-Eluting Stents and the Duration of Antiplatelet Therapy in the Post-Myocardial Infarction Period", published by him and his team in the scientific journal Heart Surgery Forum.
Dr. Dario Bottigliero’s clinical interests cover a broad spectrum of cardiovascular diseases, with expertise in acute and chronic cardiac care. He oversees a department that includes an intensive cardiac care unit (6 beds) and a non-intensive cardiology unit (20 beds). He specializes in advanced diagnostic techniques and works within a regional healthcare network, collaborating closely with the Hôpital Européen Georges Pompidou in Paris for the full spectrum of cardiac surgery, including heart transplants, and with the Hôpital de Chartres for interventional cardiology.
1. What was the primary goal of this study?
The study aimed to explore whether shortening the duration of dual antiplatelet therapy (DAPT) is a safe and effective approach for patients receiving drug-eluting stents (DES), particularly in the post-myocardial infarction period. While DES has already reduced the incidence of complications like stent thrombosis, managing the balance between preventing clots and minimizing bleeding risk remains crucial. The study, which analyzes recent clinical data, reveals that shorter DAPT regimens can substantially reduce bleeding complications without increasing the risk of thrombosis, suggesting that a more concise treatment approach may be both safe and advantageous.
2. What are the key findings or innovations in your article?
The article highlights how the development of DES has led to a shift toward shorter and safer antiplatelet therapies following percutaneous coronary interventions. It emphasizes the growing importance of personalized medicine, where individual patient characteristics help guide therapeutic decisions. Among the key innovations discussed are biodegradable stents and high-resolution imaging during procedures, which contribute to safer and more effective interventions. The article also points to future trends, including the customization of treatments based on genetic profiles and the integration of emerging technologies.
3. Do you plan to continue researching this topic in the future? If so, what are your next plans?
Yes, certainly. My team and I remain committed to researching this area. In a time when cardiology is advancing rapidly and information—sometimes inaccurate—can spread just as quickly, the role of such reviews is essential. They help establish the current state of a subject while offering accessible, peer-reviewed content.
Moving forward, we plan to focus on tailored therapy, specifically exploring the use of artificial intelligence and predictive algorithms in the management of both antiplatelet and anticoagulant therapies. The goal is to contribute to enabling more precise, patient-specific treatment strategies, ultimately optimizing care and improving patient outcomes.
4. What advice would you give to fellow scholars in this field?
Research is not limited to large academic hospitals; smaller institutions, such as community hospitals and clinics, also have valuable opportunities to engage in cardiovascular research. By collaborating with both academic and non-academic centers, these smaller institutions can expand the scope of studies, contribute important data, and gain new skills in evidence-based practice.
Therefore, my advice is to stay curious and dedicated to lifelong learning. By doing so, you can stay ahead of emerging trends and innovations in the field.
Even small teams can make a significant impact!
Read the article
Safer Heart Stents: Drug-Eluting Stents and the Duration of Antiplatelet Therapy in the Post-Myocardial Infarction Period: https://doi.org/10.59958/hsf.8273